NCT06685289 2025-01-28
Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT06609876 2024-12-03
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Sun Yat-sen University
Phase NA Recruiting
NCT06581315 2024-09-03
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase NA Recruiting
NCT06498622 2024-07-12
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
Anhui Provincial Hospital
Phase 2 Recruiting
NCT06239298 2024-06-14
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting